Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ERGO NASDAQ:GRI NASDAQ:HCM NASDAQ:INDV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERGOEntia Biosciences$0.00$0.00▼$0.00N/AN/AN/AN/AGRIGRI Bio$1.32+3.1%$1.54$1.10▼$30.43$3.20M-1.61279,703 shs279,984 shsHCMHUTCHMED$17.27-2.9%$15.99$11.51▼$21.50$3.10B0.5539,756 shs45,952 shsINDVIndivior$21.05+4.2%$14.85$7.33▼$21.09$2.79B0.653.50 million shs5.59 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERGOEntia Biosciences0.00%0.00%0.00%0.00%0.00%GRIGRI Bio+3.13%-33.67%-8.97%-37.14%-89.86%HCMHUTCHMED-2.87%-1.93%+10.07%+15.13%-11.16%INDVIndivior+4.21%+22.81%+36.69%+75.71%+53.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI Bio2.2814 of 5 stars3.54.00.00.00.60.01.3HCMHUTCHMED2.9331 of 5 stars3.33.00.00.03.30.01.9INDVIndivior1.2861 of 5 stars1.61.00.00.02.61.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERGOEntia Biosciences 0.00N/AN/AN/AGRIGRI Bio 3.00Buy$22.001,566.67% UpsideHCMHUTCHMED 2.50Moderate Buy$28.0062.13% UpsideINDVIndivior 3.20Buy$17.75-15.68% DownsideCurrent Analyst Ratings BreakdownLatest ERGO, HCM, INDV, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $28.007/22/2025INDVIndiviorJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/30/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $22.006/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERGOEntia BiosciencesN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/AHCMHUTCHMED$630.20M4.78$0.28 per share61.90$4.43 per share3.90INDVIndivior$1.17B2.48$1.90 per share11.10($2.52) per share-8.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERGOEntia BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/AGRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0011.83N/AN/AN/AN/A8/7/2025 (Estimated)INDVIndivior$2M$0.6233.9512.31N/A6.65%-85.50%16.45%N/ALatest ERGO, HCM, INDV, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GRIGRI Bio-$1.31N/AN/AN/AN/AN/A7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 million5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERGOEntia BiosciencesN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERGOEntia BiosciencesN/AN/AN/AGRIGRI BioN/A1.411.41HCMHUTCHMED0.082.832.70INDVIndiviorN/A0.880.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERGOEntia BiosciencesN/AGRIGRI Bio33.95%HCMHUTCHMED8.82%INDVIndivior60.33%Insider OwnershipCompanyInsider OwnershipERGOEntia Biosciences28.30%GRIGRI Bio0.13%HCMHUTCHMED3.60%INDVIndiviorN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERGOEntia Biosciences6N/AN/ANot OptionableGRIGRI Bio12.50 million2.49 millionNot OptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableINDVIndivior1,051137.88 millionN/ANot OptionableERGO, HCM, INDV, and GRI HeadlinesRecent News About These CompaniesBest Cannabis Stocks To Add to Your Watchlist - July 31stAugust 2 at 2:38 AM | americanbankingnews.comIndivior (INDV) Extends Jump on 3rd Day with 16% GainAugust 1 at 1:34 PM | finance.yahoo.comIndivior PLC 2025 Q2 - Results - Earnings Call PresentationAugust 1 at 5:22 AM | seekingalpha.com10 Stocks Crushing With Whopping Double-Digit GainsJuly 31 at 10:29 PM | insidermonkey.comIndivior PLC (INDV) Tops Q2 Earnings and Revenue EstimatesJuly 31 at 9:16 AM | zacks.comIndivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial GuidanceJuly 31 at 7:00 AM | prnewswire.comClark Estates Inc. NY Sells 71,125 Shares of Indivior PLC (NASDAQ:INDV)July 31 at 6:22 AM | marketbeat.comIndivior (NASDAQ:INDV) Reaches New 1-Year High - Time to Buy?July 30 at 10:40 PM | marketbeat.comLong-acting buprenorphine linked to fewer ER visits and hospital staysJuly 30 at 8:24 AM | thepharmaletter.comTNew York State Common Retirement Fund Purchases New Position in Indivior PLC (NASDAQ:INDV)July 27, 2025 | marketbeat.comBrokerages Set Indivior PLC (NASDAQ:INDV) Target Price at $17.75July 25, 2025 | americanbankingnews.comIndivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be MaintainedJuly 25, 2025 | prnewswire.comIndivior PLC (INDV) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 24, 2025 | msn.comIndivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use DisorderJuly 23, 2025 | prnewswire.comIndivior Appoints Vanessa Procter as Executive Vice President of Corporate AffairsJuly 8, 2025 | finance.yahoo.comTop Cannabis Stocks Worth Watching - July 4thJuly 4, 2025 | marketbeat.comIndivior (NASDAQ:INDV) Hits New 12-Month High - Still a Buy?July 4, 2025 | marketbeat.comIndivior (INDV) Moves 5.7% Higher: Will This Strength Last?July 1, 2025 | zacks.comIndivior Announces Inclusion in the U.S. Russell 2000® and 3000® IndexesJune 30, 2025 | uk.finance.yahoo.comIndivior Appoints Tony Kingsley to the Board of DirectorsJune 24, 2025 | finance.yahoo.comIndivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl UsersJune 19, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERGO, HCM, INDV, and GRI Company DescriptionsEntia Biosciences OTCMKTS:ERGOEntia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.GRI Bio NASDAQ:GRI$1.32 +0.04 (+3.13%) As of 08/1/2025 04:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.HUTCHMED NASDAQ:HCM$17.27 -0.51 (-2.87%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.23 -0.04 (-0.26%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Indivior NASDAQ:INDV$21.05 +0.85 (+4.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.64 -0.41 (-1.92%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
